The Zhitong Finance App learned that Biosetu-B (02315) rose by more than 13%. As of press release, it had risen 11.61% to HK$63.95, with a turnover of HK$103 million.
According to the news, with deep collaboration between the “Holistic Antibody Bank” and the “Target Humanized Mouse Bank”, Baiosetu not only achieved an overall jump in revenue and profit, but also maintained profits for 5 consecutive quarters. In the first half of this year, the company achieved revenue of 940 million yuan, an increase of 51.6% year on year; net profit to mother was 240 million yuan, a sharp increase of 402% year on year. During the reporting period, the total revenue of the preclinical sector was 723 million yuan, up 57.9% year on year, of which sales revenue of innovative animal models was 446 million yuan, up 62.4% year on year, with a gross profit margin of 82.3%; the antibody development business achieved revenue of 218 million yuan, an increase of 33.8% year on year, and maintained a high gross margin level of 92.8%.
The company has signed more than 105 new cooperation agreements, and has signed a total of 455 drug cooperative development/licensing/transfer agreements, of which more than 150 new agreements have been signed, and more than 150 cooperative pharmaceutical companies can disclose a total of tens of billions of yuan. At the same time, the company initially built RenSuper Workstation based on a million-level real whole-human antibody sequence molecular library, marking that antibody drug development is rapidly moving from the long process of “concept, one candidate, one verification” to the intelligent era of “one-click drug development”.